Life Sciences: What's new in France?

December 21, 2020

Read more about the recent developments in the life sciences sector in France.


  • The Santen decision: bad news for drug repurposing
  • Foreign direct investment control in France in time of COVID
  • Decree of 25 August 2020 on the harmonization of market access conditions: will simplification benefit to the stakeholders?
  • Avastin/Lucentis case: French Competition Authority imposes record fine of 444 million euros on Novartis and Roche for alleged abuse of collective dominant position
  • The new French anti-gift regulation is live since 1st October 2020

Read the newsletter

Subscribe to Dechert Updates